TheraGenetics fills new exec VP role
This article was originally published in Clinica
TheraGenetics (London, UK), a personalised medicine diagnostics company, has appointed Robert McBurney as executive vice-president, a newly-created role. Mr McBurney will be responsible for leading the company’s global business development and partnership strategy. He joins from BG Medicine (Massachusetts), where he served as senior vice-president, R&D and chief scientific officer. During his more than 20 years’ experience in the biopharmaceutical industry, Mr McBurney founded start-up biotech firm Differential Proteomics and has served in senior positions at Cambridge NeuroScience and at the Medical Research Council’s neuroendocrinology unit, Newcastle University, National Institutes of Health, and Cambridge University. TheraGenetics is currently commercialising a portfolio of tests to guide and improve treatment of central nervous system disorders.